Pharmacokinetics and Bioequivalence Study of Escitalopram Oxalate Formulations after Single-dose Administration in Healthy Chinese Male Volunteers

被引:3
作者
Li, Jing [1 ,2 ]
Tian, Yuan [1 ,2 ]
Zhang, Zun-Jian [1 ,2 ]
Wang, Na [1 ,2 ]
Ren, Xiaolei [1 ,2 ]
Chen, Yun [3 ,4 ]
机构
[1] China Pharmaceut Univ, Ctr Instrumental Anal, Nanjing 210009, Peoples R China
[2] China Pharmaceut Univ, Minist Educ, Key Lab Drug Qual Control & Pharmacovigilance, Nanjing 210009, Peoples R China
[3] Chinese Acad Med Sci, Inst Dermatol, Nanjing, Peoples R China
[4] Peking Union Med Coll, Nanjing, Peoples R China
来源
ARZNEIMITTELFORSCHUNG-DRUG RESEARCH | 2009年 / 59卷 / 05期
关键词
Antidepressants; Anxiolytics; CAS; 128196-01-0; 219861-08-2; Escitalopram; bioavailability; pharmacokinetics; Escitalopram oxalate;
D O I
暂无
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
The aim of the present study was to compare the bioavailability of escitalopram (CAS 128196-01-0) from two escitalopram oxalate (CAS 219861-08-2) tablets (escitalopram 10 mg tablet as test preparation and 10 mg tablet commercially available original tablet of the drug as reference preparation) in 20 Chinese healthy male volunteers, aged between 19 and 27. The study was conducted according to an open, randomized, single blind, 2-way crossover study design with a wash-out phase of 14 d. Blood samples for pharmacokinetic profiling were taken up to 156 It post-dose, and escitalopram plasma concentrations were determined with a validated liquid chromatography-electrospray ionization-mass spectrometry (LC-ESI-MS) method. Maximum plasma concentrations (C-max) of 9.85 +/- 1.79 ng/ml (test) and 9.92 +/- 2.14 ng/ml (reference) were achieved. Areas under the plasma concentration-time curve (AUC(0 - infinity)) of 428.40 +/- 140.25 ng . h/ml (test) and 413.73 +/- 144.81 ng . h/ml (reference), AUC(0 - t) of 401.33 +/- 120.61 ng . h/ml (test), 385.42 +/- 117.73 ng . h/ml (reference) were calculated. The median T-max was 4.3 +/- 1.8 h, 4.1 +/- 1.5 h for test and reference formulation, respectively. Plasma elimination half-lives (t(1/2)) of 36.30 +/- 8.93 h (test), 36.70 +/- 9.99 h (reference) were determined. Both primary target parameters, AUC(0 - infinity) and AUC(0 - t) were tested parametrically by analysis of variance (ANOVA) and relative bioavailabilities were 105.1 +/- 10.8% for AUC(0 - infinity) 104.9 +/- 11.1% for AUC(0 - t). Bioequivalence between test and reference preparation was demonstrated for both parameters, AUC(0 - infinity) and AUC(0 - t). The 90% confidence intervals of the T/R-ratios of logarithmically transformed data were in the generally accepted range of 80%-125%. That means that the test formulation is bioequivalent to the reference formulation for escitalopram.
引用
收藏
页码:228 / 232
页数:5
相关论文
共 8 条
[1]  
*CPMP EWP QWP, 2001, CPMPEWPQWP140198
[2]  
DEMORAIS SMF, 1994, J BIOL CHEM, V269, P15419
[3]  
GARDNER S, 1977, FED REGISTER, V42, P1624
[4]   The clinical pharmacokinetics of escitalopram [J].
Rao, Niranjan .
CLINICAL PHARMACOKINETICS, 2007, 46 (04) :281-290
[5]  
SCHULZ HU, 1991, INT J CLIN PHARM TH, V29, P293
[6]   Liquid chromatography-electrospray ionisation mass spectrometry method for the determination of escitalopram in human plasma and its application in bioequivalence study [J].
Singh, SS ;
Shah, H ;
Gupta, S ;
Jain, M ;
Sharma, K ;
Thakkar, P ;
Shah, R .
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 2004, 811 (02) :209-215
[7]   The pharmacokinetics of escitalopram after oral and intravenous administration of single and multiple doses to healthy subjects [J].
Sogaard, B ;
Mengel, H ;
Rao, N ;
Larsen, F .
JOURNAL OF CLINICAL PHARMACOLOGY, 2005, 45 (12) :1400-1406
[8]   Escitalopram - A review of its use in the management of major depressive and anxiety disorders [J].
Waugh, J ;
Goa, KL .
CNS DRUGS, 2003, 17 (05) :343-362